Last reviewed · How we verify
NCT04322162: ASAP
Addressing Sleep Apnea Post-Stroke/TIA
NA trial testing ASAP Intervention Quality Improvement Protocol in Ischemic Stroke in 6 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2023
Quick facts
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 6 |
| Start date | 2 April 2020 |
| Primary completion | 30 September 2023 |
| Estimated completion | 31 July 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- ASAP Intervention Quality Improvement Protocol
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Transient Ischemic Attack (TIA) — all drugs for Transient Ischemic Attack (TIA) →
- Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →
Sponsor
VA Office of Research and Development — full company profile →
Who can join
18 and older, any sex, with Ischemic Stroke or Transient Ischemic Attack (TIA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effectively identifying and treating risk factors for ischemic stroke and transient ischemic attack (TIA) is important to patients, their family members, and healthcare systems. While obstructive sleep apnea (OSA) is a known risk factor for stroke and TIA that is present in more than 70% of stroke/TIA survivors, testing for OSA is infrequently performed for patients and within healthcare systems. The Addressing Sleep Apnea Post-Stroke/TIA (ASAP) study intends to improve rates of guideline-recommended OSA testing and treatment through local quality improvement initiatives (QI) conducted within and across 6 VA Medical Centers. ASAP will also determine the impact of these local QI initiatives on rates of OSA diagnosis, OSA treatment, recurrent vascular events, and hospital readmissions.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Impact of the coronavirus disease-2019 pandemic on Veterans Health Administration Sleep Services.
Sico JJ, Koo BB, Perkins AJ, Burrone L, et al · · 2023 · cited 5× · PMID 37152838 · DOI 10.1177/20503121231169388 -
Difference-making factors in implementing a quality improvement program for sleep apnea in stroke/TIA patients.
Rattray NA, Miech EJ, Bravata DM, Story KM, et al · · 2026 · PMID 41998761 · DOI 10.1186/s43058-026-00944-9 -
Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients.
Ding Q, Sico JJ, Perkins AJ, Myers LJ, et al · · 2026 · PMID 41803896 · DOI 10.1186/s40842-026-00280-w -
Quality Improvement Intervention to Increase Sleep Apnea Diagnostic Testing After Stroke and Transient Ischemic Attack: A Cluster Randomized Trial.
Bravata DM, Perkins AJ, Myers LJ, Daggy JK, et al · · 2025 · PMID 41236739 · DOI 10.1001/jamanetworkopen.2025.43385 -
Proceedings of the 16th Annual Conference on the Science of Dissemination and Implementation in Health
· 2024 -
Patient Insights on Integrating Sleep Apnea Testing into Routine Stroke and TIA Care.
Rattray NA, Story KM, Burrone L, Sexson AE, et al · · 2024 · PMID 39742072 · DOI 10.1177/23743735241310263
Verify or expand the search:
- PubMed search for NCT04322162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
- NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care · Phase 1 · not yet recruiting
- NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran · NA · not yet recruiting
- NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness · NA · not yet recruiting
- NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans · NA · not yet recruiting
- NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04322162 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing